Rheumatoid arthritis is a chronic and systemic inflammatory disorder, which principally attacks synovial joints. It causes symmetric polyarthritis involving smaller and larger joints and extra-articular manifestations. Rheumatoid arthritis is associated with increased cardiovascular events including cardiac insufficiency, acute myocardial infarction and stroke.\[[@ref1]\] It was said that the release of pro-inflammatory cytokines and acute phase proteins are responsible for atherosclerosis.\[[@ref2]\] Cardiovascular disease (CVD) in rheumatoid arthritis patients accounts for 35% to 51% of all mortality.\[[@ref3]\] Lipoprotein (a) \[Lp (a)\] is a low-density lipoprotein (LDL) - like particle, which has apolipoprotein (A) \[apo (A)\] attached to apolipoprotein (B) \[apo (B)\] molecule via disulfide bond. There are 34 different Lp (a) isoforms depending on the size of apo (A). Lp (a) levels are influenced by apo (A) polymorphism.\[[@ref4]\]

Apolipoprotein (A) has a high degree homology with plasminogen and competes with plasminogen for fibrin binding sites and inhibits fibrinolysis. This increases plaque formation and thus promotes atherosclerosis. In addition to its role as a cholesterol carrier, Lp (a) involved in both inflammation and thrombosis. Lp (a) was significantly associated with acute phase proteins and was found to promote proliferation of vascular smooth muscle cells and chemotaxis of human monocytes. Its role in atherosclerosis was suggested by the structure of apo (A).\[[@ref5]\] Small dense lipoprotein particle also plays an important role in the atherogenic process. Small dense LDL particles are much more atherogenic than large dense LDL particle, which are easily oxidized with lower binding affinity for LDL receptors.\[[@ref6]\]

Atherosclerotic factors such as Lp (a) (or) triglyceride (TG) (or) decreased high-density lipoprotein (HDL) are involved in the atherosclerotic process. Increase in TGs an atherogenic factor, hypertriglyceridemia serve as marker for coronary artery disease (CAD).\[[@ref7]\] Lp (a) significantly increased in myocardial infarction, which is the better marker for CAD.\[[@ref8]\] Lp (a), exert independent, strong atherogenic effects.\[[@ref9]\] Hence, we conducted a study to analyze the concentrations of serum Lp (a) in patients with active rheumatoid arthritis.

Materials and Methods {#sec1-1}
=====================

The study was conducted at SRM Medical College Hospital and Research Centre, SRM Nagar, Potheri, Tamil Nadu. The study was approved by Institutional Human Ethical Committee. An informed written consent was taken from subjects and healthy controls. Thirty subjects with sero-positive rheumatoid arthritis of both genders with the age group between 25 and 80 years were considered as cases. Age- and sex-matched thirty subjects without rheumatoid arthritis was considered as controls. Patients with history of diabetes, hypertension, obesity, renal failure, liver failure and family history of hyperlipidemia, those who were on treatment with lipid-lowering agents, smoking and alcohol use were excluded from the study.

Fasting blood samples were collected from healthy subjects and patients with the sero-positive rheumatoid arthritis. Lp (a) was analyzed by immunoturbidimetry using Merk Micro lab 300 Semi-auto analyzer, ELItech Group, ELI Tech group, 9 2800 Puteaux, France. Serum total cholesterol (TC) (cholesterol oxidase method), TG (glycerol phosphate oxidase-peroxidase method) and HDL-C (precipitation assay method) were estimated by using standard enzyme kits in OLYMPUS AU 400 auto analyzer (Wendenstrabe Hamburg, Germany) on the same day of collection. LDL-C, very low density lipoprotein-cholesterol (VLDL-C) were calculated by friedewald\'s formula.

Statistical analysis {#sec2-1}
--------------------

All the data obtained were presented as mean ± standard deviation (SD). Comparisons were made between the rheumatoid arthritis patients and healthy subjects by using un-paired Student\'s *t*-test. "*P*" value of \< 0.05 was considered as significant statistically. Correlation of Lp (a) and lipid profile were calculated by Pearson\'s correlation. All the statistical analyses were performed using SPSS for Microsoft Windows, version 17.0, IBM, International.

Results {#sec1-2}
=======

[Table 1](#T1){ref-type="table"} shows a comparison of serum Lp (a) and serum lipid profile in rheumatoid arthritis patients and healthy subjects. The mean ± SD of serum Lp (a) levels in rheumatoid arthritis patients was significantly higher than that of healthy subjects (*P* \< 0.001). There was a statistically significant reduction in the concentration of serum HDL-C between rheumatoid arthritis patients and healthy subjects (*P* \< 0.05). There was no statistically significant difference (*P* \> 0.05) were observed in parameters such as serum TC, TG, LDL-C, VLDL-C between the rheumatoid arthritis patients and healthy subjects.
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In our study, the ratios of TC/HDL-C and LDL-C/HDL-C were significantly higher (*P* \< 0.05) in rheumatoid arthritis patients than healthy subjects. Serum Lp (a) correlated negatively with HDL-C, (*r* = −0.435) (*P* = 0.0016).

Discussion {#sec1-3}
==========

In our study, the serum concentration of Lp (a) was significantly increased in patients with rheumatoid arthritis. As an increased concentration of Lp (a) has been found to be closely associated with cardiovascular disease.\[[@ref10]\] Lp (a) was an important cause of cardiovascular disease in patients with rheumatoid arthritis.

Rantapää-Dahlqvist *et al.* found that the Lp (a) level in rheumatoid arthritis patients was higher than in healthy subjects.\[[@ref11]\] We also observed the same results. The effects of the inflammatory process on Lp (a) metabolism are unclear. It was suggested that increased synthesis and/or decreased destruction of Lp (a) or changes in Lp (a) distribution between intravascular and extravascular regions may cause dyslipoproteinemia in rheumatoid arthritis.\[[@ref12]\]

Since the lipid contents of Lp (a) and LDL-C were similar, they might have similar mechanisms in atherosclerosis. It is suggested that the reticulo-endothelial system became over stimulated in active rheumatoid arthritis and then the lipid elimination by scavenger receptors of macrophages increased. For that reason, Lp (a) may have a role as an important atherogenic factor.\[[@ref13]\] Dyslipoproteinemia in rheumatoid arthritis includes lower HDL-C, higher Lp (a), and higher TG and is related to atherosclerosis.\[[@ref14]\] Our study also showed that lower HDL-C, higher Lp (a) and higher TG in rheumatoid arthritis. Lazarevic *et al.* established that HDL-C levels were lower in rheumatoid arthritis patients having antilipoprotein antibodies.\[[@ref15]\] In our study also, there was a significant (*P* \< 0.05) reduction in serum HDL-C level in rheumatoid arthritis patients. This significant difference in HDL-C level between rheumatoid arthritis patients and healthy subjects might be due to physical inactivity in the former.\[[@ref14]\] Due to our rheumatoid arthritis patients had active-phase rheumatoid arthritis with various degrees of physical inactivity, in our study there was a significant reduction in serum HDL-C level. Lakatos *et al.* found that there were higher serum TC and LDL-C levels and lower HDL-C and TG levels in rheumatoid arthritis patients than in healthy subjects.\[[@ref16]\]

Lipoprotein (a) binds pro-inflammatory-oxidized phospholipids and is a preferential carrier of oxidized phospholipids.\[[@ref17]\] Apo (A) component of Lp (a) inhibits the key positive feedback step involving conversion of plasmin-mediated Glu-plasminogen to Lys-plasminogen.\[[@ref18]\] The prothrombotic, antifibrinolytic actions of apo (A) are expressed on one hand as inhibition of fibrinolysis with enhancement of clot stabilization and on the other as enhanced coagulation via the inhibition of tissue factor pathway inhibitor.\[[@ref19]\]

A reduction in cardio protective HDL-C and increase in LDL-C exposes rheumatoid arthritis patients to higher risk of CVD.\[[@ref20]\] Our study has also shown significant reduction in serum HDL-C level in rheumatoid arthritis patients. However in our study, we did not get a significant difference in serum total cholesterol, TGs, LDL-C and VLDL-C. This might be due to low number (30) in sample size. If we do this study in a large population and long-term study, this may give valuable observation.

Inflammation of rheumatoid arthritis begins with cardiovascular damage that is the early diagnosis for the increased risk of CVD. Tumor necrosis factor-α controls the inflammation and reduces the risk of CVD.\[[@ref21]\] Lp (a) with high LDL-C strongly correlated with risk of coronary heart disease.\[[@ref22]\] Elevated Lp (a) level with high LDL-C, low HDL-C and hypertension increased cardiovascular risk.\[[@ref23]\] Increased risk of atherosclerosis in rheumatoid arthritis patients has an ultrasonic marker for early atherosclerosis.\[[@ref24]\] Rheumatoid arthritis patients were found to have high levels of small dense LDL particles, and this was related to acute phase response.\[[@ref25]\] High circulating levels of small dense LDL particles constitute another characteristic feature of the metabolic syndrome.\[[@ref26]\] Furthermore, the acute phase response contributes to atherosclerosis through endothelial activation and interaction with pro-coagulant factor.\[[@ref27]\] Rheumatoid-factor (RF) positive were having higher risk of heart failure than RF negative.\[[@ref28]\] Rheumatoid arthritis patients with heart failure are related to diastolic dysfunction than without heart failure. The higher rates of heart failure in rheumatoid arthritis are due to preserved ejection fraction.\[[@ref29]\]

Conclusion {#sec1-4}
==========

Inflammatory process of rheumatoid arthritis simultaneously initiates cardiovascular damage and hence early diagnosis of rheumatoid arthritis is important along with the recognition of increased risk of cardiovascular disease. Lp (a) level may be used as a screening tool to define cardiovascular risk among this population.

Limitation {#sec2-2}
----------

Further study should be taken to overcome the following limitations.

Inclusion of the samples from various geographical distribution and large sample size will give more information on lipid profilesLong-term follow-up study will give more validated results.
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